MRI-guided Radiation Therapy Systems Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global MRI-guided Radiation Therapy Systems Market Trends and Insights

Rising Cancer Incidence and Radiotherapy Treatment Demand

Rising cancer incidence is expanding the patient population requiring radiotherapy across established and developing healthcare systems. The World Health Organization reported 20.6 million new cancer cases in 2024 and projects 35 million cases annually by 2050. This trend supports demand in the MRI-guided radiation therapy systems market, particularly for prostate, pancreatic, liver, and thoracic tumors that require precise soft-tissue and adjacent-organ visualization.^{[1]World Health Organization, “Global Status Report on Cancer 2026: The Future We Choose Together,” World Health Organization, who.int.} MRI-guided treatment supports smaller margins and adaptive radiotherapy workflows by addressing organ-motion uncertainty in conventional CT-guided planning; a 2026 review reported advantages in target localization, organ-motion management, and dosimetric control.

Adoption of Online Adaptive and Motion-Gated Radiotherapy

Online adaptive treatment is gaining traction as it enables treatment plans to respond to anatomical changes on the day of care. The MOMENTUM registry enrolled 630 patients across 12 centers in North America and Europe under NCT04075305. At the 2025 ASTRO Annual Meeting, patients receiving daily adaptive recontouring reported lower urinary symptom scores than those receiving non-adaptive MR-guided treatment: 2.2 versus 7.7 at 3 months, 3.0 versus 6.6 at 6 months, and 2.8 versus 8.8 at 12 months.^{[2]Ablative Stereotactic Magnetic Resonance-Guided Radiotherapy for Locally Advanced Pancreatic Cancer,” Cancers, mdpi.com.} A 2026 prospective phase II study reported 87.4% 2-year biochemical and clinical progression-free survival, zero late grade ≥2 toxicities, and 100% in-field control across prostate, pelvic nodal, and oligometastatic lesions, supporting procurement decisions beyond research-focused use.^{[3]“MR-Guided Online Adaptive Stereotactic Body Radiotherapy for Inoperable Pancreatic Cancer,” Radiation Oncology, springer.com.}

AI-Assisted Contouring and Synthetic CT Workflows

Artificial intelligence is reducing the time required for contouring and dose recalculation during adaptive treatment. Siemens Healthineers received the CE mark for AI contouring capabilities integrated with Eclipse at ESTRO 2026, covering more than 200 predefined structures from CT and MR images, including organs at risk, lymph nodes, and brain metastases. Synthetic CT generation supports MR-only planning by producing dose-calculation data from MRI images. A 2026 clinical validation on a 1.5 Tesla MR-Linac reported mean target-dose errors below 1% versus CT-based plans and gamma passing rates above 95% under 2 mm and 2% criteria at all sites except the thorax, helping shorten simulation-to-treatment timelines and reduce radiation exposure from positioning scans.

Expansion of High-Value Applications in Pancreatic, Liver, and Lung Cancers

Pancreatic, liver, and lung cancers require advanced treatment capabilities because tumors can move and may be located near sensitive organs. The MRI-guided radiation therapy systems market addresses these requirements through real-time imaging, adaptive planning, and motion management during beam delivery. A 2025 multi-institutional comparison found a 6.5% 2-year local failure rate for ablative stereotactic MR-guided radiotherapy in locally advanced pancreatic cancer, compared with 32.9% for CT-guided moderately hypofractionated treatment; late grade ≥3 toxicity was 2.2% and 9.2%, respectively.^{[4]“Treatment Time in MRI-Guided Radiotherapy,” Frontiers in Oncology, frontiersin.org.} A prospective 2025 study reported 80.2% local control at both 6 months and 1 year for inoperable pancreatic cancer treated with MR-guided online adaptive SBRT, while 97% of patients reported pain relief at 3 months; real-time tumor tracking and predictive gating for central lung tumors are also expanding treatment eligibility on 1.5 Tesla systems.^{[5]“Comparison of MR-Linac Platforms Under MIRAGE and SMART Protocols,” Cancers, mdpi.com.}

High Capital, Installation and Maintenance Costs

MR-Linac deployment requires significant capital investment in shielding, specialized infrastructure, commissioning, and ongoing service support. These requirements create challenges for smaller hospitals and health systems with limited medical physics resources. MagnetTx designed Aurora-RT with a cryogen-free 0.5 Tesla superconducting magnet and rotating gantry, eliminating liquid-helium refill requirements. Siemens Healthineers offers the 0.55 Tesla MAGNETOM Free.Max RT Pro Edition, featuring a 165 cm system length and a quench-pipe-free design for facilities with infrastructure constraints. However, equipment selection, regulatory compliance, quality assurance, and workforce capacity continue to complicate procurement.

Limited Reimbursement and Incomplete Comparative Clinical Evidence

Reimbursement remains a key constraint, as many payer systems have not established separate payment pathways for adaptive MR-guided treatment. Payers in the United States, Germany, and the United Kingdom often require randomized evidence against best-practice conventional image-guided radiotherapy. The MIRAGE trial reported lower acute grade 2 or higher urinary toxicity with MRI-guided prostate SBRT than with CT-guided treatment, at 24% versus 70%, along with lower gastrointestinal toxicity. However, inconsistent reimbursement differentiation continues to require institutions to rely on research funding, subsidies, or high-volume treatment commitments.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Product Type: Integrated MR-Linac Systems Hold the Leading Position

Integrated MR-Linac systems accounted for 67.88% of the MRI-guided radiation therapy systems market share in 2025 and are projected to grow at a 16.39% CAGR through 2031. These systems combine MRI and a linear accelerator within a single treatment platform, supporting real-time visualization during beam delivery for targets affected by anatomical changes or motion. Full integration provides greater clinical control than workflows using separately located imaging and treatment systems. Elekta Unity remains the commercially established 1.5 Tesla integrated platform with the broadest cited multicenter clinical evidence base.

A 2025 dosimetric comparison of 20 MRIdian clinical cases recreated on Unity found comparable plan quality across the platforms. Unity showed modest reductions in rectal V36-40Gy for prostate cases and mean liver dose for pancreatic cases. These results support the continued use of integrated systems for complex disease sites.

By MRI Field Strength: High-Field Systems Lead While Low-Field Systems Expand Access

The 1.5 Tesla segment held 55.45% of the MRI-guided radiation therapy systems market share in 2025. Its leadership reflects the superior soft-tissue imaging quality available at higher magnetic field strengths. High-field systems have developed a substantial clinical evidence base through prostate registries, glioma research, and emerging lung-treatment studies. The UNITED glioma trial was published in The Lancet Oncology in 2026.

Systems in the 0.3 Tesla to 0.5 Tesla range are forecast to grow at a 15.34% CAGR through 2031. Their growth reflects lower infrastructure requirements, simpler siting, and designs that manage the electron return effect. ViewRay MRIdian uses a 0.35 Tesla split MRI configuration with the beam perpendicular to the magnetic field. MagnetTx Aurora-RT uses a 0.5 Tesla rotating biplanar magnet with the beam parallel to the field, avoiding the electron return effect without beam-modeling corrections. Siemens Healthineers offers the 0.55 Tesla MAGNETOM Free. Max RT Pro Edition is an MR-simulation system that can be installed near existing treatment rooms. These architectures provide oncology providers with multiple pathways to MRI-enabled radiotherapy. Lower-field systems can be relevant in India, China, and other Asia-Pacific markets where a 1.5 Tesla installation may be difficult to support.

By Clinical Application: Prostate Cancer Leads Revenue and Lung Cancer Grows Fastest

Prostate cancer held 32.80% of the MRI-guided radiation therapy systems market share in 2025—the application benefits from the need to protect the bladder, rectum, and neurovascular structures during treatment. Long-standing evidence has linked treatment precision with genitourinary outcomes for patients with prostate cancer. The ERECT sub-study of the MOMENTUM consortium reported lower patient-reported erectile dysfunction with neurovascular-sparing MR-guided radiotherapy.

Lung cancer is projected to grow at a 15.88% CAGR through 2031, driven by advances in respiratory gating and real-time tumor tracking for thoracic treatment. A 2026 review found that diffusion-weighted imaging and cine-MRI ventilation mapping on 0.35 Tesla and 1.5 Tesla systems showed feasibility for biological response-adaptive treatment of lung tumors. The MRI-guided radiation therapy systems industry can benefit if these workflows become more routine for moving thoracic targets.

By End User: Hospitals Lead Current Demand and Cancer Centers Expand Rapidly

Hospitals held 64.38% of the MRI-guided radiation therapy systems market share in 2025. Hospital campuses can better accommodate the shielding, power requirements, and infrastructure associated with existing 1.5 Tesla installations. They also support broad oncology case mixes, including prostate, pancreatic, liver, lung, and other disease sites. This patient base can help justify the operating costs of a dedicated MR-Linac program.

Dedicated cancer centers are forecast to expand at a 16.78% CAGR through 2031. These centers can use MR-Linac capacity to differentiate their precision radiotherapy offerings from conventional linac services. Their oncology focus enables specialized teams to align equipment utilization with selected prostate, pancreatic, and thoracic patient groups. Cancer networks in Asia-Pacific and the Gulf are expanding alongside broader investment in oncology services.

Geography Analysis

North America held 42.80% of the MRI-guided radiation therapy systems market share in 2025. The region benefits from National Cancer Institute-designated cancer centers, established radiation physics training programs, and reimbursement advocacy for adaptive radiotherapy. The United States accounts for a significant installed base, with clinical programs at Moffitt Cancer Center, Washington University, and UCLA, while Elekta signed a collaboration agreement with Moffitt Cancer Center in February 2025. Canada contributes through MagnetTx Oncology Solutions and the Northern Lights Clinical Consortium; however, reimbursement and treatment throughput remain key barriers to broader deployment.

Europe is the second-largest region in the MRI-guided radiation therapy systems market. Medical centers across Germany, the Netherlands, the United Kingdom, France, and Spain support multicenter registries and clinical validation. Institut Curie activated an Elekta Unity MR-Linac at its Saint-Cloud site in March 2025, supported by EUR 10 million (USD 11.61 million) in institutional and government funding. Siemens Healthineers received CE marking for Eclipse AI contouring integration at ESTRO 2026, while health technology assessment and tariff decisions in Germany and the United Kingdom will influence broader adoption.

Asia-Pacific is projected to grow at a CAGR of 14.56% through 2031, driven by rising cancer burden, public oncology infrastructure investment, and expanding cancer-center networks. India introduced its first Elekta Unity MR-Linac with Comprehensive Motion Management at Yashoda Medicity in Hyderabad in 2025, while China initiated institutional procurement, including a single-source tender by Ruijin Hospital affiliated with Shanghai Jiao Tong University School of Medicine. Japan began clinical treatment with a 1.5 Tesla MR-Linac in December 2021, although adoption remains concentrated around Kanto cancer centers. South Korea, Australia, the Middle East and Africa, and South America represent additional demand areas, with Brazil leading oncology-capacity investment in South America; infrastructure and workforce limitations will influence adoption.